BRAF and central nervous system cancer: Additionally, IDH mutations often co‐occur with glioma‐associated genetic alterations including BRAF, TERT promoter, 1p/19q co‐deletion, and MGMT promoter methylation,[31] which may also result in shifts of metabolic pathways and the spatial heterogeneity of H2O2/GSH ratio.